UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
17.39 x 3 17.75 x 10
Post-market by (Cboe BZX)
17.37 -0.66 (-3.66%) 04/22/25 [NASDAQ]
17.39 x 3 17.75 x 10
Post-market 17.40 +0.03 (+0.17%) 17:50 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
17.01
Day High
18.36
Open 18.22
Previous Close 18.03 18.03
Volume 2,769,900 2,769,900
Avg Vol 2,759,060 2,759,060
Stochastic %K 8.48% 8.48%
Weighted Alpha -67.82 -67.82
5-Day Change -1.96 (-10.14%) -1.96 (-10.14%)
52-Week Range 17.01 - 50.98 17.01 - 50.98
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,263,054
  • Shares Outstanding, K 125,516
  • Annual Sales, $ 781,370 K
  • Annual Income, $ -197,880 K
  • EBIT $ -165 M
  • EBITDA $ -153 M
  • 60-Month Beta 0.85
  • Price/Sales 2.92
  • Price/Cash Flow N/A
  • Price/Book 9.91

Options Overview Details

View History
  • Implied Volatility 84.54% ( +4.36%)
  • Historical Volatility 57.42%
  • IV Percentile 90%
  • IV Rank 80.59%
  • IV High 92.86% on 07/18/24
  • IV Low 49.96% on 01/23/25
  • Put/Call Vol Ratio 0.72
  • Today's Volume 464
  • Volume Avg (30-Day) 975
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 32,219
  • Open Int (30-Day) 33,503

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 13
  • High Estimate -0.17
  • Low Estimate -0.47
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.01 +2.12%
on 04/22/25
Period Open: 24.14
24.88 -30.17%
on 03/27/25
-6.77 (-28.04%)
since 03/21/25
3-Month
17.01 +2.12%
on 04/22/25
Period Open: 30.39
31.17 -44.27%
on 01/23/25
-13.02 (-42.84%)
since 01/22/25
52-Week
17.01 +2.12%
on 04/22/25
Period Open: 47.64
50.98 -65.93%
on 04/26/24
-30.27 (-63.54%)
since 04/22/24

Most Recent Stories

More News
Apellis Announces Craig Wheeler to Join the Board of Directors

APLS : 17.37 (-3.66%)
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

APLS : 17.37 (-3.66%)
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

APLS : 17.37 (-3.66%)
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

APLS : 17.37 (-3.66%)
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

APLS : 17.37 (-3.66%)
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

APLS : 17.37 (-3.66%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

APLS : 17.37 (-3.66%)
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

APLS : 17.37 (-3.66%)
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

APLS : 17.37 (-3.66%)
Apellis Announces Keli Walbert to Join the Board of Directors

APLS : 17.37 (-3.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 19.50
2nd Resistance Point 18.93
1st Resistance Point 18.15
Last Price 17.37
1st Support Level 16.80
2nd Support Level 16.23
3rd Support Level 15.45

See More

52-Week High 50.98
Fibonacci 61.8% 38.00
Fibonacci 50% 33.99
Fibonacci 38.2% 29.99
Last Price 17.37
52-Week Low 17.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro